Form D · Pharmaceuticals
Intellipharmaceutics International Inc.
Toronto, A6 · CIK 0001474835
Offering snapshot reported Apr 3, 2018 · SEC filing
- Reported sold
- $1.01M Offering amount: $1.01M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 19, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 3, 2018 | Initial | $1,012,500 | No comparison | 5 | SEC filing |
| Mar 21, 2018 | Initial | $1,968,750 | No comparison | 5 | SEC filing |
| Oct 18, 2017 | Initial | $2,522,728 | No comparison | 6 | SEC filing |
| Feb 15, 2011 | Initial | $12,000,000 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $126K
- Finders' fees
- $0
- Form D file number
- 021-309248
Represents the aggregate warrant exercise price for the warrants covered by this Form D, which were issued in a private placement ("PP") conducted concurrently with a registered direct offering ("RDO") of common shares not the subject of this Form D.
H.C. Wainwright Co., LLC ("Wainwright") received the above sales commissions, and $35,000 in expense reimbursements in connection with the RDO and the PP of the warrants. Wainwright also received warrants to purchase an aggregate of 150,000 common shares.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright Co., LLC | 375 |
Source: Form D, filed Apr 3, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John N. Allport | Director, Executive |
| Michael Campbell | Executive |
| Kenneth Keirstead | Director |
| Bahadur Madhani | Director |
| Amina Odidi | Director, Executive |
| Isa Odidi | Director, Executive |
| Andrew Patient | Executive |
| Shameze Rampertab | Executive |
| Eldon Smith | Director |
| Patrick N. Yat | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
30 Worcester Road
Toronto, A6, M9W 5X2
Toronto, A6, M9W 5X2